Viridian Therapeutics
Most recent annual filing: 2026-02-15
- VRDN-006 corporate update2026VRDN-006 corporate update, 2026, routine
- VRDN-008 Ph1 readout2H 2026VRDN-008 Ph1 readout, 2H 2026, material
- Anti-TSHR Antibody IND filing4Q 2026Anti-TSHR Antibody IND filing, 4Q 2026, notable
- TSHR program IND filing4Q 2026TSHR program IND filing, 4Q 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
elegrobart
VRDN-003VRDN-006
- Undisclosed indication
VRDN-008
- Undisclosed indication
anti-TSHR antibody
Biotech Distilled coverage (9)
- 2026-08-07 UPDATE: Viridian Therapeutics (VRDN) - The Launch Quarter With No Launch Revenue 🔒 Paid
- 2026-06-26 UPDATE: Viridian Therapeutics (VRDN) - Lumvoa Lands Four Days Early 🔒 Paid
- 2026-05-26 UPDATE: Viridian Therapeutics (VRDN) - The WuXi Doubling Down 🔒 Paid
- 2026-05-14 UPDATE: Viridian Therapeutics (VRDN) - Fairmount Doubles Down at $17 🔒 Paid
- 2026-05-08 UPDATE: Viridian Therapeutics (VRDN) - The Dilution Prints 🔒 Paid
- 2026-05-06 UPDATE: Viridian Therapeutics (VRDN) - The Chronic TED Redemption Arc, Now With a Dilution Chaser 🔒 Paid
- 2026-03-31 UPDATE: Viridian Therapeutics (VRDN) REVEAL-1 Update 🔒 Paid
- 2026-03-01 UPDATE: Viridian (VRDN) - FY25 Update 🔒 Paid
- 2026-02-05 Viridian Therapeutics (VRDN): Scientific Deep Dive for Veligrotug, Elegrobart, and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.